Scientists at The University of Texas Health Science Center at Houston (UTHealth) are testing the effectiveness of a soy-enriched aspirin formulation designed to fight colorectal cancer with fewer side effects.
Lenard Lichtenberger, Ph.D., professor of integrative biology and pharmacology at McGovern Medical School at UTHealth, is the principal investigator for the preclinical study funded with a $1.9 million grant from the National Cancer Institute (NCI). The grant was awarded to PLx Pharma Inc., the specialty pharmaceutical company developing this new form of aspirin.
The research into the chemopreventive action of aspirin is so conclusive that the U.S. Preventive Services Task Force recommends that people between the ages of 50 and 69 take low-dose aspirin on a daily basis to prevent colorectal cancer so long as they consult with their physician first.
While aspirin reduces the risk of colorectal cancer, daily use can cause ulcers and stomach bleeding. Colorectal cancer is a leading cause of cancer death in the United States, claiming more than 50,000 lives in 2013, according to the Centers for Disease Control and Prevention.
“We want to learn more about the link between aspirin and colorectal cancer,” said Lichtenberger, who developed the compound being tested in conjunction with colleagues at PLx Pharma Inc. The FDA-approved drug is called Aspertec,™ and it works by reducing damage to the lining of the gastrointestinal tract.
Lichtenberger and his colleagues in the cancer study at Baylor College of Medicine and The University of Texas MD Anderson Cancer Center are particularly interested in how aspirin inhibits a key component of colorectal tumor growth – platelet activity. “Platelet activity has been tied to tumor growth, and I strongly believe and have evidence that aspirin’s chemopreventive activity is linked to the powerful anti-platelet activity of the drug,” Lichtenberger said.
Lichtenberger’s team will be testing the cancer protective properties of both aspirin and Aspertec™ as well as the effects of the medications on the lining of the gastrointestinal tract.
Previously reported research by Lichtenberger and his colleagues revealed how Aspertec™ slows platelet development in preclinical models of colorectal cancer.
Lichtenberger’s collaborators on the NCI-funded research include Elizabeth Dial, Ph.D., and Dexing Fang, Ph.D., of McGovern Medical School; Scott Kopetz, M.D., Ph.D., and Ernest Hawk, M.D., M.P.H., of the MD Anderson Cancer Center and Vinod Vijayan, Ph.D., of Baylor College of Medicine.
Lichtenberger and Kopetz are on the faculty of The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at Houston.